Recursion dazzled investors with a tantalizing pitch: We are a biotech scaling more like a tech company.
The potential to boost the scale and efficiency of drug development by automating wet labs and applying machine learning to the resulting data led investors to hand Recursion $502 million to take four drugs into phase 2 and advance six other programs up to the cusp of the clinic.
The company has advanced its internal pipeline while continuing business development activities.
